Uscom Limited (UCM) AI Stock Analysis

• Market Cap: AU$2.86M
• Dividend Yield: N/A
• Average Volume (3M): 88.38K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.55
• Revenue Growth: 2.91%
• EPS Growth: 13.51%
• Country: AU
• Employees: 35
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 260,147,130
• 10 Day Avg. Volume: 30,407
• 30 Day Avg. Volume: 88,376
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

The overall stock score is driven by financial instability and bearish technical indicators. While Uscom Limited is growing revenue, persistent profitability issues and negative cash flow are major concerns. The technical outlook is weak, with oversold conditions indicating potential for further declines. The valuation reflects risk due to ongoing losses.

Uscom Limited Business Overview & Revenue Model

Company Description

Uscom Limited (UCM) is a medical technology company specializing in the development, manufacturing, and marketing of non-invasive cardiovascular and pulmonary medical devices. The company's core products include advanced hemodynamic monitoring systems and spirometers, which are used in various healthcare settings for the assessment and management of heart and lung health.

How the Company Makes Money

Uscom Limited generates revenue primarily through the sale of its medical devices to hospitals, clinics, and healthcare professionals. The company's key revenue streams include direct sales of its hemodynamic monitoring systems and spirometers, as well as ongoing service and maintenance contracts. Additionally, Uscom may engage in partnerships or collaborations with healthcare institutions and research organizations, contributing to its earnings through joint ventures and co-development agreements.

Uscom Limited Financial Statement Overview

Summary

Uscom Limited shows revenue growth but struggles with consistent profitability, negative EBIT, and net income. The balance sheet indicates manageable leverage but declining equity ratios and negative cash flow metrics suggest financial instability.

Income Statement

Uscom Limited shows a fluctuation in its revenue, with a notable increase in the recent year. However, the company has consistently reported negative EBIT and net income, indicating ongoing profitability challenges. While the gross profit has improved, the net profit margin remains negative, which is a significant concern.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio, suggesting manageable leverage levels. However, the equity ratio has been declining, indicating potential risks in asset management. The return on equity has been negative, highlighting the company's struggle to generate profit from its equity base.

Cash Flow

Cash flow analysis reveals persistent negative free cash flow, though operating cash flow has shown some improvement in recent periods. The free cash flow to net income ratio remains unfavorable, suggesting that the company is facing challenges in converting profits into cash.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	3.73M	2.66M	2.51M	3.86M	3.48M
Gross Profit	3.12M	-1.03M	-1.21M	781.70K	458.00K
EBITDA	-1.51M	-2.53M	-1.84M	-833.84K	-672.88K
Net Income	-2.07M	-2.59M	-1.97M	-924.24K	-1.33M
Balance Sheet
Total Assets	5.13M	5.18M	7.99M	5.33M	5.92M
Cash, Cash Equivalents and Short-Term Investments	2.52M	2.18M	4.70M	1.71M	1.92M
Total Debt	989.28K	1.09M	1.31M	1.43M	1.62M
Total Liabilities	2.07M	2.14M	2.06M	2.26M	2.50M
Stockholders Equity	3.06M	3.04M	5.94M	3.08M	3.42M
Cash Flow
Free Cash Flow	-1.22M	-1.58M	-1.08M	21.63K	-321.38K
Operating Cash Flow	-1.16M	-1.42M	-967.51K	54.98K	-283.23K
Investing Cash Flow	-57.55K	-151.94K	-115.31K	-33.35K	-38.16K
Financing Cash Flow	1.57M	-952.96K	4.05M	-281.87K	1.03M

Uscom Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:UCM, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of <0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 9.09 is Positive, neither overbought nor oversold. The STOCH value of -38.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:UCM.

Uscom Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.38B	-0.04	-62.85%	2.34%	15.18%	-2.87%
AT1	50 Neutral	AU$15.75M	―	-61.15%	―	35.63%	18.55%
ADR	47 Neutral	AU$7.45M	―	-375.15%	―	-59.01%	17.13%
UCM	46 Neutral	AU$2.86M	―	-117.20%	―	2.91%	13.51%
HMD	45 Neutral	AU$16.64M	―	-321.94%	―	-39.97%	55.29%
CBL	44 Neutral	AU$13.26M	―	-98.08%	―	-7.44%	30.34%
IRX	38 Underperform	AU$7.90M	―	-191.40%	―	―	19.74%

Uscom Limited Corporate Events

Uscom Limited Navigates Market Challenges with Strategic Focus

Uscom Limited reported a challenging Q4 2025 with a decrease in customer receipts and cash on hand compared to previous periods, attributed to global market instability. Despite these challenges, Uscom is focusing on cost control, expanding sales and distribution partnerships, and developing growth strategies for a market rebound. The company continues product development, with its BP+ technology gaining recognition and regulatory approval for its SpiroSonic devices in China, positioning Uscom for future growth in the global medical device market.

Uscom Limited Secures A$2 Million in Short-Term Loans for Working Capital

Uscom Limited has secured two short-term loans totaling A$2,000,000 to bolster its working capital. The loans, one from Executive Chairman Assoc. Prof Robert Phillips and another from Jetan Pty Limited, each carry a 15% interest rate and are unsecured, with repayment due by June 30, 2026. This financial maneuver is expected to support Uscom’s operational liquidity and potentially strengthen its market position.

Uscom Limited Director Increases Shareholding Through Performance Rights Conversion

Uscom Limited announced a change in the director’s interest, with Robert Allan Phillips converting 9,670,117 performance rights into ordinary shares, increasing his total holdings to 93,958,881 shares. This conversion, approved at the 2024 AGM, reflects a strategic move to align the director’s interests with the company’s growth, potentially impacting stakeholder confidence and market perception positively.

Uscom Limited Issues New Shares to Bolster Growth

Uscom Limited has issued 9,670,117 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant legal provisions. This strategic move could potentially enhance the company’s financial standing and operational capacity, reflecting its commitment to growth and adherence to regulatory standards.

Uscom Limited Issues New Securities to Strengthen Market Position

Uscom Limited has announced the issuance of 9,670,117 new ordinary fully paid securities, which will be quoted on the ASX starting July 7, 2025. This move is part of the company’s strategy to enhance its capital structure, potentially impacting its market position and providing opportunities for growth and expansion in the medical technology sector.